Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Here Is What Hedge Funds Think Of Coherus Biosciences Inc (CHRS)

Page 1 of 2

We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the government. The 13F filings show the funds’ and investors’ portfolio positions as of September 30. In this article we look at what those investors think of Coherus Biosciences Inc (NASDAQ:CHRS).

Coherus Biosciences Inc (NASDAQ:CHRS) investors should pay attention to a decrease in activity from the world’s largest hedge funds of late. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as Rexford Industrial Realty Inc (NYSE:REXR), Zoe’s Kitchen Inc (NYSE:ZOES), and Cosan Limited (USA) (NYSE:CZZ) to gather more data points.

Follow Coherus Biosciences Inc. (NASDAQ:CHRS)
Trade (NASDAQ:CHRS) Now!

If you’d ask most investors, hedge funds are perceived as slow, outdated financial tools of yesteryear. While there are more than an 8000 funds trading today, Our researchers look at the bigwigs of this club, around 700 funds. These money managers control most of the smart money’s total asset base, and by observing their unrivaled equity investments, Insider Monkey has uncovered various investment strategies that have historically outstripped the market. Insider Monkey’s small-cap hedge fund strategy beat the S&P 500 index by 12 percentage points a year for a decade in their back tests.

Now, let’s review the key action encompassing Coherus Biosciences Inc (NASDAQ:CHRS).

Hedge fund activity in Coherus Biosciences Inc (NASDAQ:CHRS)

At the end of the third quarter, a total of 17 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of -11% from the previous quarter. With hedgies’ capital changing hands, there exists a select group of key hedge fund managers who were upping their holdings significantly (or already accumulated large positions).

Of the funds tracked by Insider Monkey, Peter Kolchinsky’s RA Capital Management has the largest position in Coherus Biosciences Inc (NASDAQ:CHRS), worth close to $26.2 million, amounting to 3.8% of its total 13F portfolio. Sitting at the No. 2 spot is VHCP Management, managed by Anders Hove and Bong Koh, which holds a $17.4 million position; the fund has 4.5% of its 13F portfolio invested in the stock. Other peers that hold long positions contain Jason Karp’s Tourbillon Capital Partners, Bihua Chen’s Cormorant Asset Management and Christopher James’s Partner Fund Management.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!